Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GORG - 002 Randomized Phase III Trial to Determine the Effectiveness of High Dose Versus Standard Dose of Vitamin D2 (Ergocalciferol) Given With Docetaxel in Patients With Metastatic Breast Cancer

NCT00944424 is registered in ClinicalTrials.gov with King Faisal Specialist Hospital & Research Center as lead sponsor.

NCT NCT00944424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00944424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GORG - 002 Randomized Phase III Trial to Determine the Effectiveness of High Dose Versus Standard Dose of Vitamin D2 (Ergocalciferol) Given With Docetaxel in Patients With Metastatic Breast Cancer
Lead sponsor
King Faisal Specialist Hospital & Research Center
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2009
Completion date
July 31, 2012
Enrollment
260 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer